Choroidal neovascularization (CNV) with chorioretinal atrophy is the most common cause of poor vision in patients with pathologic myopia.[@ref1] In India, refractive errors are a major cause of treatable blindness. Population surveys in southern India have shown prevalence of high myopia to be 4.32-4.54%.[@ref2]-[@ref4] Pathologic myopia is also common in Asian countries like Singapore (prevalence of 9%[@ref5]). This is high compared to a prevalence of 2% in the United States.[@ref6]

Pathologic myopia is associated with progressive stretching and thinning of the posterior pole and choroid with loss of choriocapillaries. The elongation of the globe causes vascular alterations, breaks in Bruch′s membrane (lacquer cracks) with increased risk of CNV.[@ref7] Photodynamic therapy (PDT) uses photosensitive verteporfin which selectively collects in proliferating endothelial cells within the target CNV and on activation, cytotoxic reactive oxygen intermediates damage the cellular proteins and cause microvascular thrombosis without a direct thermal effect.[@ref8]

The natural course of the disease without treatment is unfortunately poor but better visual outcomes have been reported with PDT, compared to laser and submacular surgery.[@ref9]-[@ref17] The VIP Study Group, a randomized controlled trial for treatment of pathological myopia using verteporfin recommended PDT.[@ref18] Complications of treatment[@ref19] and the cost, particularly in less developed countries should be borne in mind when treating these patients. The alternatives to PDT such as in anti-vascular endothelial growth factor (anti-VEGF) therapy[@ref20],[@ref21] and combination treatments[@ref22] are also promising.

We have reported earlier the one-year data in myopic patients.[@ref23] The present study reports on the outcome after a two-year follow-up of patients treated with verteporfin PDT for CNV caused by pathologic myopia in a tertiary care hospital in south India.

Materials and Methods
=====================

We reviewed the prospectively collected data of patients receiving PDT with verteporfin for subfoveal CNV secondary to pathologic myopia during the period from May 2001 to June 2005. All patients underwent ocular examination in each visit which included:

ETDRS letter acuity (best corrected) at 4 metersDilated slit-lamp biomicroscopyDilated fundus examination (+ 90 D and + 20 D)Color fundus photographFundus fluorescein angiography (FFA)

The inclusion and exclusion criteria and method of treatment were similar as published earlier.[@ref23] Briefly, the inclusion criteria were best corrected visual acuity ≥ 20/200; myopia ≥ 6 diopter; fundus changes characteristic of chorioretinal atrophy, lacquer cracks and posterior staphyloma and age ≥ 18 years. The exclusion criteria were history of previous macular laser, intraocular surgery in the last three months and other ocular disorders possibly causing CNV (viz. Angioid streaks and age-related macular degeneration).

Patients who completed at least 24 months follow-up were included in the study. The follow-up schedule was every three months. All the tests were repeated on each follow-up visit.

The primary outcome measure was visual outcome and secondary outcome was the number of retreatments. Improvement was defined as a gain of th \> 10 ETDRS letters, deterioration as a loss of \> 10 ETDRS letters and stabilization as \< 10 letters gain or loss. Success was defined as improvement or stabilization of vision.

Wilcoxon signed rank test was used to see the difference in the mean letter acuity at intervals compared to the baseline. Kaplan Meier Survival analysis was done to estimate the success rate of verteporfin therapy for CNV caused by pathologic myopia.

Photodynamic therapy with verteporfin for CNV caused by pathologic myopia and the study protocol had been approved by the ethics committee of the institute in 2001.

Results
=======

The age range of these 15 patients (eight male and seven female) was from 28 to 57 years (41 + 10.02). Right eye was affected in eight patients. The mean spherical equivalent was -13.46 + 5.88 diopter (range: -6.0 to -25.0 diopter). All patients completed at least 24 months follow-up.

At the baseline, four out of 15 eyes had visual acuity (VA) ≥ 20/40, six eyes out of 15 had between 20/50 and 20/80; and five eyes out of 15 had ≥ 20/200. At 24 months, four eyes out of 15 each had VA ≥ 20/40 and between 20/50 and 20/80 respectively, and seven eyes out of 15 had ≥ 20/200 \[[Figure 1](#F1){ref-type="fig"}\].

\[[Figure 2](#F2){ref-type="fig"}\] shows the trend of mean letter acuity over a period of 24 months. At six months, there was significant improvement in mean letter acuity (33.8 + 12.4) from baseline (27.4 + 15.2) (*P*=0.02), but there was no difference at 12 (*P*=0.3), 18 (*P*=0.9) and 24 months (*P*=0.95). Compared to improvement in letter acuity in the first six months, there was reduction in mean letter acuity at 18 (28.1 + 14.8) (*P*=0.02) and 24 months (27.3 + 14.3) (*P*=0.05).

Five out of 15 eyes at six months, three out of 15 eyes at 12 and 18 months, and four out of 15 at 24 months follow-up gained ≥ 10 letters \[[Figure 3](#F3){ref-type="fig"}\].

Survival analysis showed a success rate of 100% at six months, 93.3% (SE=0.064) at 12 months and 73.3% (SE=0.114) at 24 months.

The mean number of PDT treatment session was 2.2 (Range: 1- 5, Mode: 2). It was 2.06 (range: 1-5) in the first year and 0.13 (range: 0 -2) in the second year. Retinal pigment epithelial collateral change was seen in five out of 15 eyes.

Discussion
==========

Presence of subfoveal CNV is one of the major causes of decreased vision in pathologic myopia (5-10%) besides progression of myopic macular chorioretinal atrophy.[@ref23],[@ref24] Moreover, high myopia is common in the Asian population[@ref24],[@ref25] compared to the Caucasian population (2-4%).[@ref25] The VIP Study has shown the beneficial effect of PDT and demonstrated that verteporfin therapy improves the chance of stabilization (\< 8 letters loss) or causes improvement of vision compared to either natural history or placebo at least at 24 months follow up.[@ref18]

The present study has demonstrated that verteporfin therapy is beneficial in stabilization of vision at 24 months. Significant improvement of vision was seen at six months (*P*=0.02) from baseline but did not maintain till 24 months. Actually, a drop in visual acuity (VA) was seen after 12 months and the VA at 24 months was not significantly different from the baseline visual acuity. We have reported initial improvement of vision with verteporfin therapy in the first six months in neovascular age- related macular degeneration.[@ref26] Even though the mean visual acuity change at 24 months was not statistically significant, at least four out of 15 of eyes gained ≥ 10 letters and there was a success rate of 73.3% (S.E: 0.114) at the end of follow-up. The 24 months′ experience of a case series of 22 Asian Chinese eyes have also shown no statistical difference in mean best corrected visual acuity (*P*=0.5).[@ref11] Initial improvement of vision noted in the first three months did not sustain for two years. We had shown in our earlier report[@ref23] that eight of nine eyes had unchanged vision at the end of one year following PDT. The current report suggests that the trend is nearly similar and PDT stabilizes the vision in high myopic eyes with CNV.

In our study cohort, the mean number of treatment was 2.2 in 24 months and interestingly, 93.6% of the treatment (2.06) was required in the first year itself. This was almost similar to the report by Lam *et al*.,[@ref11] (mean treatment rate of 2.3) in 24 months. This may suggest that chances of recurrence of CNV needing treatment or requiring retreatment in the second year are minimal. The VIP study showed a higher mean treatment rate of 5.1 at 24 months in Caucasian eyes.[@ref18]

Though PDT is helpful in stabilizing vision in pathologic myopia with CNV, currently there are other alternatives and options which were not available at the time of the study duration. While the anti-VEGF therapy has largely taken over as the primary treatment mode in subfoveal CNV, the role of PDT is still considered and tried the world over. Since the mechanism of actions is different, there could be a role for both PDT and anti-VEGF therapy in the future. Our study shows a limited role of PDT, and possibly today, combined with the anti-VEGF therapy could be more beneficial than PDT alone as shown in past.[@ref27]

Thus, this study shows that verteporfin therapy in subfoveal CNV caused by pathologic myopia is equally effective in Indian eyes and compares well with the study in Asian Chinese eyes from Hong Kong. It may be possible that some ethnic variation may exist even amongst the Asian population. The ethnic variation between Asian and Caucasian population is not clearly known. This disparity may be due to more pigments in retinal pigmented epithelium providing a possible protective effect.[@ref11]
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